Dextroamphetamine Study Should Avoid Prior Stimulant Use, Pediatric Cmte. Says
This article was originally published in The Pink Sheet Daily
FDA committee accepts recommendation from its Pediatric Ethics Subcommittee to allow a study of dextroamphetamine in healthy children to proceed. Stimulants should not be provided to participants prior to enrollment, committee says.
You may also be interested in...
NIH proposal to administer dextroamphetamine to healthy children represents only a slightly greater than minimal risk to study participants, FDA's Pediatric Ethics Subcommittee says. The Pediatric Advisory Committee will review the recommendations Sept. 15.
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.
Sanofi-Aventis will price its meningococcal conjugate vaccine Menactra in line with Wyeth's pneumococcal vaccine Prevnar